{"id":61015,"date":"2024-02-28T07:20:47","date_gmt":"2024-02-28T07:20:47","guid":{"rendered":"https:\/\/medsname.com\/udiliv\/"},"modified":"2026-04-30T10:23:39","modified_gmt":"2026-04-30T10:23:39","slug":"udiliv","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/udiliv\/","title":{"rendered":"Udiliv"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:0 0 18px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Snelle antwoord<\/h3>\n<p><strong>Udiliv<\/strong> bevat <strong>ursodeoxycholic acid (UDCA) 300 mg<\/strong> per tablet \u2014 the higher-strength form of UDCA for primary biliary cholangitis (PBC), cholesterol gallstone dissolution, intrahepatic cholestasis of pregnancy and other cholestatic liver disorders. The 300 mg strength halves daily pill count compared to the 150 mg form (Ursodec).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f6f8;border:1px solid #e1e4e8;border-radius:4px;padding:14px 18px;margin:18px 0;display:flex;flex-wrap:wrap;gap:14px;font-size:0.95em;\"><span>\u2705 <strong>WHO-GMP gecertificeerd<\/strong> fabrikant<\/span><span>\ud83d\udce6 <strong>Discrete verpakking<\/strong><\/span><span>\ud83c\udf0d <strong>Wereldwijde verzending<\/strong><\/span><span>\ud83d\udcac <a href=\"\/nl\/reviews\/\">1.400+ klantbeoordelingen<\/a><\/span><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<h2>What ursodeoxycholic acid is<\/h2>\n<p>Ursodeoxycholic acid (UDCA, also called ursodiol) is a naturally occurring secondary bile acid. Therapeutically it does three things at once: it <strong>displaces cytotoxic hydrophobic bile acids<\/strong> (chenodeoxycholic, deoxycholic, lithocholic) from the bile-acid pool, it <strong>reduces biliary cholesterol secretion<\/strong> (which dissolves cholesterol gallstones over months), and it <strong>protects cholangiocytes<\/strong> from bile-acid-mediated injury through cytoprotective and immunomodulatory effects. It is the only oral therapy with mortality and transplant-free survival benefit in primary biliary cholangitis (Poupon 1991, 1994; meta-analyses 2002, 2014).<\/p>\n<h2>Indicaties<\/h2>\n<ul>\n<li><strong>Primaire biliaire cholangitis (PBC)<\/strong> \u2014 first-line therapy; 13\u201315 mg\/kg\/day in divided doses with meals. ~60\u201370% biochemical response (alkaline phosphatase normalisation or significant fall) over 12 months. Non-responders are switched or augmented with obeticholic acid or fibrates.<\/li>\n<li><strong>Cholesterol gallstone dissolution<\/strong> \u2014 for radiolucent stones &lt; 15 mm in a functioning gallbladder, in patients who cannot or will not have cholecystectomy. 8\u201310 mg\/kg\/day for 6\u201324 months. Stone recurrence after cessation is significant (\u2248 50% at 5 years).<\/li>\n<li><strong>Primary sclerosing cholangitis (PSC)<\/strong> \u2014 improves biochemistry; mortality benefit not proven. High-dose (28\u201330 mg\/kg\/day) is associated with worse outcomes and is contraindicated.<\/li>\n<li><strong>Intrahepatic cholestasis of pregnancy (ICP)<\/strong> \u2014 10\u201315 mg\/kg\/day (or 500 mg twice daily); reduces maternal pruritus and bile acid levels; may reduce fetal complications.<\/li>\n<li><strong>Niet-alcoholische leververvetting (NAFLD)<\/strong> \u2014 biochemistry improves but high-quality histological benefit is unproven; not a first-line NAFLD therapy in current guidelines.<\/li>\n<li><strong>Cystic fibrosis associated liver disease<\/strong> \u2014 used in paediatric and adult CF cholestasis.<\/li>\n<\/ul>\n<h2>Dosering<\/h2>\n<table>\n<thead>\n<tr>\n<th>Indicatie<\/th>\n<th>Dose (mg\/kg\/day)<\/th>\n<th>Schema<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>PBC<\/td>\n<td>13\u201315<\/td>\n<td>2\u20133 divided doses with meals<\/td>\n<\/tr>\n<tr>\n<td>Cholesterol gallstone dissolution<\/td>\n<td>8\u201310<\/td>\n<td>2 divided doses (with the largest dose at bedtime)<\/td>\n<\/tr>\n<tr>\n<td>PSC<\/td>\n<td>13\u201315 (do NOT exceed 28 mg\/kg)<\/td>\n<td>2\u20133 divided doses<\/td>\n<\/tr>\n<tr>\n<td>ICP (pregnancy)<\/td>\n<td>10\u201315<\/td>\n<td>2 divided doses<\/td>\n<\/tr>\n<tr>\n<td>NAFLD adjunct<\/td>\n<td>13\u201315<\/td>\n<td>2\u20133 divided doses<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Vermijd bij<\/h3>\n<ul>\n<li>Acute cholecystitis, cholangitis or biliary obstruction<\/li>\n<li>Calcified or pigment gallstones (no dissolution effect)<\/li>\n<li>Non-functioning gallbladder on oral cholecystography<\/li>\n<li>Severe hepatic decompensation (Child-Pugh C) \u2014 discuss with hepatology<\/li>\n<\/ul>\n<\/div>\n<h2>Bijwerkingen<\/h2>\n<p>Generally very well tolerated. Most common: mild diarrhoea (5\u201310%), abdominal discomfort, nausea, mild rash. Pruritus may transiently worsen in PBC during the first weeks before improving. Rarely: gallstone calcification (radio-opaque shift) on long courses.<\/p>\n<h2>Geneesmiddelinteracties<\/h2>\n<ul>\n<li><strong>Bile acid sequestrants (cholestyramine, colesevelam, colestipol)<\/strong> \u2014 bind UDCA in the gut and reduce absorption. Separate by \u2265 4\u20135 hours.<\/li>\n<li><strong>Aluminiumbevattende antacida<\/strong> \u2014 bind UDCA. Separate by \u2265 2 hours.<\/li>\n<li><strong>Oestrogens, oral contraceptives, clofibrate<\/strong> \u2014 increase biliary cholesterol saturation and antagonise the gallstone-dissolution effect.<\/li>\n<li><strong>Ciprofloxacin, dapsone<\/strong> \u2014 modestly altered absorption; clinically minor.<\/li>\n<\/ul>\n<h2>Zwangerschap en borstvoeding<\/h2>\n<p>Used routinely off-label in intrahepatic cholestasis of pregnancy with extensive safety data. Compatible with breastfeeding (excreted in trace amounts in milk; no infant harm reported).<\/p>\n<h2>Opslag<\/h2>\n<p>Store below 25 \u00b0C in a dry place, original packaging. Tablets are stable for the full labelled shelf life when kept dry.<\/p>\n<h3>Waarom bestellen bij MedsBase<\/h3>\n<p>Udiliv is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/nl\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Uw betalingsbeschrijving bij betaling per kaart toont de gereguleerde betalingsverwerker (een gereguleerde kaartbetalingverwerker), nooit \"MedsBase\" of een medicijnnaam.<\/p>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3>How long until I see results in primary biliary cholangitis?<\/h3>\n<p>Alkaline phosphatase typically falls within 4\u20138 weeks and the trajectory at 12 months predicts long-term outcome. The Toronto, Paris-1 and Paris-2 criteria define a &#8220;biochemical responder&#8221; at 1 year by ALP, AST and bilirubin thresholds. Non-responders should discuss obeticholic acid or fibrate add-on with hepatology.<\/p>\n<h3>Can UDCA dissolve any kind of gallstone?<\/h3>\n<p>Only cholesterol stones, only if radiolucent on imaging, only in a functioning gallbladder, and only if &lt; 15 mm. Calcified, pigment, or partially calcified stones do not respond.<\/p>\n<h3>Why does my doctor want me on UDCA forever for PBC?<\/h3>\n<p>PBC is a chronic autoimmune cholangitis. UDCA changes the disease trajectory but does not cure it. Stopping UDCA is followed by biochemical relapse within weeks. Lifelong therapy at 13\u201315 mg\/kg\/day is standard.<\/p>\n<h3>Kan ik het gebruiken tijdens de zwangerschap?<\/h3>\n<p>Yes \u2014 UDCA is the standard treatment for intrahepatic cholestasis of pregnancy. Decades of use show no fetal harm, and it reduces maternal pruritus and bile acid levels.<\/p>\n<h3>Will UDCA cause weight loss or weight gain?<\/h3>\n<p>Neither, in most patients. Mild diarrhoea may cause minor early weight loss in a small fraction.<\/p>\n<h3>Does UDCA work for non-alcoholic fatty liver?<\/h3>\n<p>It improves biochemistry (ALT, AST). Whether it improves liver histology and outcomes is not established in large trials. Current NAFLD\/NASH guidelines do not recommend UDCA as routine therapy.<\/p>\n<h3>Can I drink alcohol on UDCA?<\/h3>\n<p>Most patients on UDCA have an underlying liver condition. Alcohol is best avoided altogether in PBC, PSC and significant hepatic disease.<\/p>\n<h3>What is the difference between UDCA and bile salts in supplements?<\/h3>\n<p>UDCA is a specific bile acid (ursodeoxycholic). Generic &#8220;bile salt&#8221; supplements are mixtures of natural bile acids without therapeutic dose standardisation. Only purified UDCA tablets are used clinically for PBC and gallstone dissolution.<\/p>\n<h3>How is UDCA monitored?<\/h3>\n<p>For PBC: ALP, ALT, AST, GGT, total bilirubin every 3 months for the first year, then 6-monthly. For gallstone dissolution: ultrasound at 6, 12, and 24 months to track stone size.<\/p>\n<h3>Can high-dose UDCA be harmful?<\/h3>\n<p>In primary sclerosing cholangitis, doses \u2265 28 mg\/kg\/day were associated with WORSE clinical outcomes (Lindor 2009 NEJM). Stick to 13\u201315 mg\/kg\/day in PSC and never escalate without specialist input.<\/p>\n<h2>Other Liver &#038; Hepatology Products<\/h2>\n<ul>\n<li><a href=\"\/nl\/ursodec\/\">Ursodec (UDCA 150 mg) \u2014 lower-strength UDCA, finer dose granularity<\/a><\/li>\n<li><a href=\"\/nl\/hepatitis-medication\/\">All Hepatitis &amp; Liver Medications<\/a><\/li>\n<li><a href=\"\/nl\/hepcinat\/\">Hepcinat (sofosbuvir) \u2014 direct-acting antiviral for chronic HCV<\/a><\/li>\n<li><a href=\"\/nl\/myhep-all\/\">MyHep All (sofosbuvir + velpatasvir) \u2014 pan-genotypic HCV<\/a><\/li>\n<li><a href=\"\/nl\/celin\/\">Celin (vitamin C) \u2014 antioxidant adjunct<\/a><\/li>\n<li><a href=\"\/nl\/l-glutathione-250mg\/\">L-Glutathione 250 mg \u2014 antioxidant for hepatic redox support<\/a><\/li>\n<\/ul>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0 0 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Medische Disclaimer<\/h3>\n<p style=\"margin:0;\">Deze informatie is uitsluitend bedoeld voor educatieve doeleinden en is geen vervanging voor medisch advies. Raadpleeg altijd een gekwalificeerde zorgverlener voordat u met een medicatie begint, deze wijzigt of stopt.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u2705 Dissolves gallstones<br \/>\n\u2705 Relieves bile blockage<br \/>\n\u2705 Protects liver cells<br \/>\n\u2705 Reduces liver inflammation<br \/>\n\u2705 Verbeterde leverfunctie<\/p>\n<p>Udiliv contains Ursodeoxycholic Acid.<\/p>","protected":false},"featured_media":61016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334],"product_tag":[4965,4728],"class_list":{"0":"post-61015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_tag-udiliv","10":"product_tag-ursodeoxycholic-acid","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/61015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=61015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/61016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=61015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=61015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=61015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=61015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}